This press release details AbbVie's financial performance for the second quarter of 2025, highlighting increased net revenues of $15.423 billion and an adjusted diluted EPS of $2.97. The report provides a breakdown of revenues across key portfolios, including strong growth in Immunology and Neuroscience, while Aesthetics saw a decrease. It also outlines recent product approvals and clinical trial results for drugs like Rinvoq and Emrelis, as well as strategic collaborations and acquisitions aimed at expanding AbbVie's pipeline. Finally, the company raised its full-year 2025 adjusted diluted EPS guidance, reflecting confidence in its continued momentum.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana